Overactive Bladder/Enuresis

FDA: Energy-Based Devices Should Not Be Used for Vaginal "Rejuvenation"

By July 31, 2018

The Agency has become aware of some manufacturers marketing these devices for vaginal "rejuvenation" or vaginal cosmetic procedures.

FDA Approves Nocdurna for Nocturia Due to Nocturnal Polyuria

By June 22, 2018

Nocdurna carries a Boxed Warning for hyponatremia.

AUA: Most Women Report Dysfunctional Toileting Behaviors

May 21, 2018

Overall, 79.9, 64.5, and 97.8% reported premature voiding, straining to void, and delayed voiding, respectively.

FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria Launched

By May 01, 2018

Noctiva was approved by the Food and Drug Administration (FDA) in March 2017 based on findings from two 12-week, randomized, double-blind, placebo-controlled trials (N=1045) in patients with nocturia due to nocturnal polyuria.

FDA Approves Myrbetriq Combo Treatment for Overactive Bladder

By April 30, 2018

In clinical trials, the combination of Myrbetriq + solifenacin succinate was associated with greater improvements in the number of incontinence episodes per 24 hours (primary endpoint), the number of micturations per 24 hours (primary endpoint), and the volume voided per micturation (secondary endpoint) compared to placebo or to individual active components.

Anticholinergic Drug Use and Dementia: What's the Link?

By April 26, 2018

A total of 14,453 (35%) cases and 86,403 (30%) controls were prescribed at least 1 anticholingeric drug with an Anticholinergic Cognitive Burden (ACB) score of 3; 1429 (3.5%) cases and 7909 (2.8%) controls were prescribed drugs with an ACB score of 2; most patients (89% of cases and 87% of controls) received a drug with an ACB score of 1 during the drug exposure period (DEP).

FDA Clears UriVarx Test Strips for UTI Detection

By January 11, 2018

The supplements are intended to reduce urinary urgency, accidents, and day/night frequency in patients with overactive bladder and urinary infections.

Multiple Sclerosis Treatment Highlights

By September 13, 2017

MPR interviewed Dr. John Stoffel to discuss the strategies for diagnosis and management of urinary retention in MS patients, as well as his recommendations for optimal care for these patients.

Astellas Seeks Approval for Overactive Bladder Combo Therapy

By June 30, 2017

"We look forward to FDA's review of our application for a potential new treatment option for the millions of people living with OAB," said Bernhardt Zeiher, MD, president of Development at Astellas.

Acupuncture Examined in Incontinence, Infertility

June 28, 2017

"The use of acupuncture with or without clomiphene, compared with control acupuncture and placebo, did not increase live births," the authors write.

AZO Line Expands with New Bladder Control Supplement

By May 23, 2017

The supplement contains pumpkin seed and soy germ extract, and Synetrim CQ, a botanical that further promotes bladder control by aiding metabolic health and managing weight.

Overactive Bladder Tx Tied to Depressive Disorders

April 13, 2017

The researchers followed over 10,000 women for 3 years to assess the risk of depressive disorders associated with antimuscarinics.

Botox Injection Efficacy Examined in Overactive Bladder

April 10, 2017

The researchers found that for treatment of overactive bladder, the safety and efficacy of intradetrusor injection of onabotulinumtoxin A is sensitive to injection volume and depth.

Overactive Bladder Tx Tied to Depression in Women

By April 06, 2017

The researchers hypothesized that some antimuscarinics with "high lipophilicity, neutral polarity, or low molecular size still cross the blood-brain barrier and further affect neurotransmission in the brain," which could possibly trigger the depressive symptoms.

Concerns Raised Over Commonly Prescribed OAB Drug

March 28, 2017

Among elderly patients, oxybutynin was frequently prescribed and continued; incidence, 27.3%; prevalence, 33.2%.

Noctiva Approved for Nocturia Due to Nocturnal Polyuria

By March 06, 2017

The approval was based on two 12-week, randomized, double-blind, placebo-controlled trials that included 1,045 patients 50 years of age and older with nocturia due to nocturnal polyuria.

New Skin Protectant Available to Prevent Incontinence-Associated Dermatitis

By February 01, 2017

3M announced the launch of Cavilon Advanced Skin Protectant for the prevention of moderate to severe incontinence-associated dermatitis (IAD).

FDA Committee Votes in Favor of Nocturia Drug

By October 20, 2016

The Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee voted 14-4 in favor of the benefit risk profile of the New Drug Application (NDA) for SER120 (desmopressin nasal spray; Allergan and Serenity). In addition, the Committee voted 17-1 regarding the evidence in favor of at least one of the doses being effective.

Study Compares OnabotulinumtoxinA to InterStim for Female Urinary Incontinence

October 05, 2016

Compared with sacral neuromodulation, onabotulinumtoxinA resulted in a small improvement

Long-Term OnabotulinumtoxinA Evaluated for Overactive Bladder

August 17, 2016

OnabotulinumtoxinA treatment is safe and effective for long-term treatment of overactive bladder syndrome, according to a study published in the September issue of The Journal of Urology.

FDA Approves OTC Device to Help with Urinary Incontinence

By July 13, 2016

Analytica announced that the Food and Drug Administration (FDA) has approved PeriCoach at-home pelvic floor trainer device and smartphone app as an over-the-counter (OTC) treatment for mild, moderate, and stress urinary incontinence (UI) and urge incontinence.

Do SSRI/SNRIs Affect Nighttime Urinary Frequency?

By May 11, 2016

Selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) do not appear to significantly impact nocturnal urinary frequency, researchers from Albany Medical College, Albany, NY, reported.

Nasal Spray May Provide Relief for Nocturia Patients

May 10, 2016

A nasal spray may provide relief for patients struggling with nocturia, while other research highlights the positive benefits of exercise on the condition.

Rate of Potentially Inappropriate Med Use in OAB Tx Warrants Intervention

April 13, 2016

For older adults starting antimuscarinic treatment for overactive bladder (OAB), potentially inappropriate medication (PIM) use is highly prevalent and associated with greater total costs.

Food Reference App Helps Patients Choose Bladder-Friendly Foods

By December 15, 2015

An app produced by the Interstitial Cystitis Network (ICN) may bring some relief to patients with urinary disorders looking to avoid foods that may provoke the pain and discomfort of their condition.

Overactive Bladder Drug to Be Discontinued

By October 28, 2015

The decision to discontinue the product is business-related and not due to product safety or efficacy.

Botox for OAB: New Long-Term Results on Safety, Efficacy

By October 16, 2015

llergan announced results from an extension study of two Phase 3 trials on the long-term safety and efficacy of Botox (onabotulinumtoxinA) in female patients with overactive bladder (OAB) with symptoms of urge urinary incontinence.

Noninvasive Tx Promising for Stress Urinary Incontinence

September 29, 2015

Noninvasive erbium:yttrium-aluminum-garnet (Er:YAG) laser treatment appears promising for stress urinary incontinence (SUI) in women.

Myrbetriq Gains New Contraindication, Warning

August 12, 2015

The Food and Drug Administration (FDA) has approved changes to the Myrbetriq (mirabegron; Astellas Pharma) label to include a new contraindication and a new update to the Warnings and Precautions section.

New Evidence Can Help Informed Choice in Incontinence Surgery

July 06, 2015

An intervention review indicates that mid-urethral sling (MUS) operations are a highly effective treatment for stress urinary incontinence (SUI) in women; however, complication rates and long-term need for repeat surgery are factors for patients to consider when choosing a procedure.